Scleroderma is a rare autoimmune disease characterized by skin thickening and hardening, often affecting internal organs such as the lungs and kidneys. According to the American College of Rheumatology, it accounts for around 8 to 56 new cases per million people annually, with a higher prevalence in females. Scleroderma pipeline analysis by Expert Market Research highlights promising developments in pulmonary arterial scleroderma treatments, including antifibrotic agents and monoclonal antibodies. The growing focus on targeted biologics and immunomodulators is driving innovation in scleroderma therapeutics. Moreover, with increased R&D investments and clinical trials, the scleroderma pipeline is expected to witness significant growth in the coming years.
Major companies involved in the scleroderma pipeline analysis include Novartis Pharmaceuticals, AstraZeneca, and others.
Leading drugs currently in the pipeline include Divozilimab, Tibulizumab, CABA-201, and others.
The rising clinical trial activity targeting fibrosis, advancements in biologics, and focused research on IL-6 and TGF-β pathway inhibitors are key drivers in the scleroderma pipeline.
The Scleroderma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into scleroderma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for scleroderma. The scleroderma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The scleroderma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with scleroderma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to scleroderma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Scleroderma is a rare autoimmune disorder that causes the hardening and tightening of the skin and connective tissues due to excess collagen production. It occurs when the immune system mistakenly attacks the body, leading to inflammation and fibrosis that may affect the skin, blood vessels, and internal organs. Scleroderma is classified into localized types (like morphea and linear, affecting skin) and systemic types (limited and diffuse, involving internal organs and skin).
Scleroderma treatment focuses on symptom relief, slowing disease progression, and preventing complications through immunosuppressants, anti-inflammatory drugs, and organ-specific therapies. In February 2024, Certa Therapeutics’ FT011 received fast-track designation from the United States Food and Drug Administration as a potential disease-modifying treatment for systemic sclerosis, showing significant clinical improvement in Phase II studies.
The global epidemiological profile of scleroderma indicates incidence rates of 8 to 56 new cases per million persons annually, predominantly affecting female patients. A systematic review published in 2019 investigated systemic sclerosis (SSc) epidemiology studies conducted in Europe and the United States. In Europe, prevalence estimates range from 7.2 to 33.9 per 100,000 individuals, while North American rates vary from 13.5 to 44.3 per 100,000. Increasing incidence trends among older individuals highlight the evolving burden of the disease.
This section of the report covers the analysis of scleroderma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 40.74%, covers a major share of the total scleroderma clinical trials, highlighting robust clinical progress and growing therapeutic confidence. Phase I follows at 35.19%, reflecting strong early-stage research. Phase III holds 11.11%, indicating promising late-stage developments. Early Phase I accounts for 7.41%, and Phase IV holds 5.56%, ensuring post-marketing evaluation. This dynamic pipeline positively drives innovation in the scleroderma market.
The drug molecule categories covered under the scleroderma pipeline analysis include small molecules, monoclonal antibodies, biologics, cell therapies, RNA-based therapies, gene therapies, and others. The scleroderma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for scleroderma.
Chimeric antigen receptor (CAR) T cell therapies are emerging as promising immune-based treatments for scleroderma. For example, KYV-101, a fully human anti-CD19 CAR T cell therapy, is under investigation in a phase 1/2 trial for diffuse cutaneous systemic sclerosis. It aims to achieve deep B-cell depletion, potentially resetting the immune system and reducing disease activity.
The EMR report for the scleroderma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed scleroderma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in scleroderma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for scleroderma. It includes product description, trial ID, study type, drug class, mode of administration, and the recruitment status of scleroderma drug candidates.
Divozilimab is a monoclonal antibody targeting CD20, developed by Biocad CJSC. It is a part of a Phase III trial that is evaluating its efficacy and safety in patients with active systemic scleroderma. The study is enrolling adults meeting ACR/EULAR 2013 criteria. The drug works through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), aiming to reduce immune cell activity and improve skin and lung function.
Tibulizumab, sponsored by Zura Bio Inc., is undergoing Phase II clinical development. The study is assessing the efficacy, safety, and tolerability of Tibulizumab in adults with systemic sclerosis. Tibulizumab is a humanized, tetravalent bispecific antibody targeting IL-17A and BAFF, aiming to reduce inflammation and fibrosis in systemic sclerosis patients.
CABA-201 is a fully human CD19-CAR T cell therapy sponsored by Cabaletta Bio. The Phase 1/2 study, RESET-SSc, is currently evaluating its safety and efficacy in patients with systemic sclerosis. This investigational drug is being administered as a single dose, combined with cyclophosphamide and fludarabine, aiming to target B cells responsible for autoimmunity and tissue fibrosis.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Scleroderma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for scleroderma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into scleroderma collaborations, regulatory environments, and potential growth opportunities.
Global Scleroderma Therapeutics Market Report and Forecast
Upto 25% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share